| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Departments of Pathology [C. R., S. K., W. M. B., D. W. C., R. H. H., M. G.], Oncology [M. L. Z., D. W. C., C. J. Y., R. H. H., M. G.], Medicine [M. C., M. G.], and Surgery [K. D. L., J. L. C., C. J. Y.], The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205-2196; The Institut National de la Santé et de la Recherche Médicale U-370 and Liver Unit, Centre Hospitalier Universitaire Necker, 75015 Paris, France [L. C.]; and The Service d’Anatomie et de Cytologie Pathologiques, Hôpital Européen Georges Pompidou, 75015 Paris, France [F. C.]
New biomarkers of pancreatic adenocarcinoma are needed to improve the early detection of this deadly disease. We performed surface enhanced laser desorption ionization (SELDI) mass spectrometry using ProteinChip technology (Ciphergen Biosystems, Fremont, CA) to screen for differentially expressed proteins in pancreatic juice. Pancreatic juice samples obtained from patients undergoing pancreatectomy for pancreatic adenocarcinoma were compared with juice samples from patients with other pancreatic diseases. We identified a peak 
16,570 daltons present in the pancreatic juice from 10/15 (67%) of the patients with pancreatic adenocarcinoma and in the pancreatic juice from 1/7 (17%) of the patients with other pancreatic diseases. Using a ProteinChip immunoassay, we identified this differentially expressed protein as hepatocarcinoma-intestine-pancreas/pancreatitis-associated-protein I (HIP/PAP-I), a protein released from pancreatic acini during acute pancreatitis and overexpressed in hepatocellular carcinoma. We then quantified by ELISA the pancreatic juice HIP/PAP-I levels in 43 patients (28 with pancreatic adenocarcinoma, 15 with other pancreatic diseases) and the serum HIP/PAP-I levels in 98 patients (53 with pancreatic adenocarcinoma, 45 with other pancreatic diseases or healthy individuals). HIP/PAP-I levels were significantly higher in both the pancreatic juice (P < 0.001) and in the serum (P < 0.001) of patients with pancreatic adenocarcinoma compared with the control group. HIP/PAP-I levels were 1000-fold higher in pancreatic juice compared with serum and the magnitude of the difference between the pancreatic adenocarcinoma group and the control group was greater in the pancreatic juice samples (143.75 ± 235.52 µg/ml versus 6.04 ± 7.59 µg/ml) than in the serum samples (99.96 ± 140.66 ng/ml versus 35.25 ± 28.44 ng/ml). In our study, patients with pancreatic juice HIP/PAP-I levels 
20 µg/ml were 21.9 times (95% confidence interval, 3.5–136.5; P < 0.001) more likely to have pancreatic adenocarcinoma than patients with levels <20 µg/ml. Immunolabeling of tissue sections revealed that the HIP/PAP-I protein was strongly expressed in acini adjacent to the invasive adenocarcinoma, but it was only rarely (1/30; 3%) expressed in the neoplastic epithelium, which suggests that the main source of HIP/PAP-I release in the pancreatic juice is acini. This low level of HIP/PAP-I expression in pancreatic adenocarcinoma was confirmed by reverse transcription-PCR: only 1 (5%) of 19 pancreatic cancer cell lines expressed HIP/PAP-I transcripts. Taken together, these data suggest that pancreatic juice measurement of HIP/PAP-I may help to identify patients with pancreatic adenocarcinoma.
This article has been cited by other articles:
|
|
 |
|
  G. Feldmann and A. Maitra Molecular Genetics of Pancreatic Ductal Adenocarcinomas and Recent Implications for Translational Efforts J. Mol. Diagn., March 1, 2008; 10(2): 111 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. McLerran, W. E. Grizzle, Z. Feng, W. L. Bigbee, L. L. Banez, L. H. Cazares, D. W. Chan, J. Diaz, E. Izbicka, J. Kagan, et al. Analytical Validation of Serum Proteomic Profiling for Diagnosis of Prostate Cancer: Sources of Sample Bias Clin. Chem., January 1, 2008; 54(1): 44 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Rodrigues, J. A. Teixeira, F. L. Schmitt, M. Paulsson, and H. Lindmark-Mansson The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1087 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Melle, G. Ernst, N. Escher, D. Hartmann, B. Schimmel, A. Bleul, H. Thieme, R. Kaufmann, K. Felix, H. M. Friess, et al. Protein Profiling of Microdissected Pancreas Carcinoma and Identification of HSP27 as a Potential Serum Marker Clin. Chem., April 1, 2007; 53(4): 629 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakagawa, S. K. Huang, S. R. Martinez, A. N. Tran, D. Elashoff, X. Ye, R. R. Turner, A. E. Giuliano, and D. S.B. Hoon Proteomic Profiling of Primary Breast Cancer Predicts Axillary Lymph Node Metastasis Cancer Res., December 15, 2006; 66(24): 11825 - 11830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-R. Ho, Y.-C. Lou, W.-C. Lin, P.-C. Lyu, W.-N. Huang, and C. Chen Human Pancreatitis-associated Protein Forms Fibrillar Aggregates with a Native-like Conformation J. Biol. Chem., November 3, 2006; 281(44): 33566 - 33576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. de Bont, M. L. den Boer, R. E. Reddingius, J. Jansen, M. Passier, R. H.N. van Schaik, J. M. Kros, P. A.E. Sillevis Smitt, T. H. Luider, and R. Pieters Identification of Apolipoprotein A-II in Cerebrospinal Fluid of Pediatric Brain Tumor Patients by Protein Expression Profiling Clin. Chem., August 1, 2006; 52(8): 1501 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Muller, G. Ernst, C. Melle, R. Guthke, and F. von Eggeling Convergence of the proteomic pattern in cancer Bioinformatics, June 1, 2006; 22(11): 1293 - 1296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Dev., May 15, 2006; 20(10): 1218 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Koopmann, C. N. W. Rosenzweig, Z. Zhang, M. I. Canto, D. A. Brown, M. Hunter, C. Yeo, D. W. Chan, S. N. Breit, and M. Goggins Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9 Clin. Cancer Res., January 15, 2006; 12(2): 442 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ernst, C. Melle, B. Schimmel, A. Bleul, and F. von Eggeling Proteohistography--Direct Analysis of Tissue with High Sensitivity and High Spatial Resolution Using ProteinChip Technology J. Histochem. Cytochem., January 1, 2006; 54(1): 13 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, R. Orlandi, C. N. White, J. Rosenzweig, J. Zhao, E. Seregni, D. Morelli, Y. Yu, X.-Y. Meng, Z. Zhang, et al. Independent Validation of Candidate Breast Cancer Serum Biomarkers Identified by Mass Spectrometry Clin. Chem., December 1, 2005; 51(12): 2229 - 2235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Goggins Molecular Markers of Early Pancreatic Cancer J. Clin. Oncol., July 10, 2005; 23(20): 4524 - 4531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Shaw, D. G. Kirsch, and T. Jacks Future of Early Detection of Lung Cancer: The Role of Mouse Models Clin. Cancer Res., July 1, 2005; 11(13): 4999s - 5003s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Chen, S. Pan, T. A. Brentnall, and R. Aebersold Proteomic Profiling of Pancreatic Cancer for Biomarker Discovery Mol. Cell. Proteomics, April 1, 2005; 4(4): 523 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Koomen, L. N. Shih, K. R. Coombes, D. Li, L.-c. Xiao, I. J. Fidler, J. L. Abbruzzese, and R. Kobayashi Plasma Protein Profiling for Diagnosis of Pancreatic Cancer Reveals the Presence of Host Response Proteins Clin. Cancer Res., February 1, 2005; 11(3): 1110 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Posadas, F. Simpkins, L. A. Liotta, C. MacDonald, and E. C. Kohn Proteomic analysis for the early detection and rational treatment of cancer--realistic hope? Ann. Onc., January 1, 2005; 16(1): 16 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. F. Yang, D. W. Ho, C. T. Lam, J. M. Luk, C. T. Lum, W. C. Yu, R. T. Poon, and S. T. Fan Identification of Brain-Derived Neurotrophic Factor as a Novel Functional Protein in Hepatocellular Carcinoma Cancer Res., January 1, 2005; 65(1): 219 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. J. Semmes, Z. Feng, B.-L. Adam, L. L. Banez, W. L. Bigbee, D. Campos, L. H. Cazares, D. W. Chan, W. E. Grizzle, E. Izbicka, et al. Evaluation of Serum Protein Profiling by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for the Detection of Prostate Cancer: I. Assessment of Platform Reproducibility Clin. Chem., January 1, 2005; 51(1): 102 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Wetmore and B. A. Merrick Invited Review: Toxicoproteomics: Proteomics Applied to Toxicology and Pathology Toxicol Pathol, October 1, 2004; 32(6): 619 - 642. [Abstract] [PDF]
|
|
|
|
|
|
S. Skates and O. Iliopoulos Molecular Markers for Early Detection of Renal Carcinoma: Investigative Approach Clin. Cancer Res., September 15, 2004; 10(18): 6296S - 6301S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Melle, G. Ernst, B. Schimmel, A. Bleul, S. Koscielny, A. Wiesner, R. Bogumil, U. Moller, D. Osterloh, K.-J. Halbhuber, et al. A Technical Triade for Proteomic Identification and Characterization of Cancer Biomarkers Cancer Res., June 15, 2004; 64(12): 4099 - 4104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koopmann, P. Buckhaults, D. A. Brown, M. L. Zahurak, N. Sato, N. Fukushima, L. J. Sokoll, D. W. Chan, C. J. Yeo, R. H. Hruban, et al. Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers Clin. Cancer Res., April 1, 2004; 10(7): 2386 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koopmann, N. S. Fedarko, A. Jain, A. Maitra, C. Iacobuzio-Donahue, A. Rahman, R. H. Hruban, C. J. Yeo, and M. Goggins Evaluation of Osteopontin as Biomarker for Pancreatic Adenocarcinoma Cancer Epidemiol. Biomarkers Prev., March 1, 2004; 13(3): 487 - 491. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Sato, N. Fukushima, A. Maitra, C. A. Iacobuzio-Donahue, N. T. van Heek, J. L. Cameron, C. J. Yeo, R. H. Hruban, and M. Goggins Gene Expression Profiling Identifies Genes Associated with Invasive Intraductal Papillary Mucinous Neoplasms of the Pancreas Am. J. Pathol., March 1, 2004; 164(3): 903 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koopmann, Z. Zhang, N. White, J. Rosenzweig, N. Fedarko, S. Jagannath, M. I. Canto, C. J. Yeo, D. W. Chan, and M. Goggins Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry Clin. Cancer Res., February 1, 2004; 10(3): 860 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Macgregor Biomarkers of Cancer Risk and Therapeutic Benefit: New Technologies, New Opportunities, and Some Challenges Toxicol Pathol, January 1, 2004; 32(1_suppl): 99 - 105. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Rogers, P. Clarke, J. Noble, N. P. Munro, A. Paul, P. J. Selby, and R. E. Banks Proteomic Profiling of Urinary Proteins in Renal Cancer by Surface Enhanced Laser Desorption Ionization and Neural-Network Analysis: Identification of Key Issues Affecting Potential Clinical Utility Cancer Res., October 15, 2003; 63(20): 6971 - 6983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Melle, G. Ernst, B. Schimmel, A. Bleul, S. Koscielny, A. Wiesner, R. Bogumil, U. Moller, D. Osterloh, K.-J. Halbhuber, et al. Biomarker Discovery and Identification in Laser Microdissected Head and Neck Squamous Cell Carcinoma with ProteinChip(R) Technology, Two-dimensional Gel Electrophoresis, Tandem Mass Spectrometry, and Immunohistochemistry Mol. Cell. Proteomics, July 1, 2003; 2(7): 443 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Petricoin and L. A. Liotta Clinical Applications of Proteomics J. Nutr., July 1, 2003; 133(7): 2476S - 2484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. Petricoin and L. A. Liotta Mass Spectrometry-based Diagnostics: The Upcoming Revolution in Disease Detection Clin. Chem., April 1, 2003; 49(4): 533 - 534. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
